Loading articles…
Loading articles…
Research included in this condition report
61 rights-cleared articles matching the governed report scope, ordered newest first.
61 articles
Newest firstSublingual (SL) drug delivery represents an important alternative route of analgesic administration, particularly in settings where rapid pain control is desired or oral and parenteral routes are limited. By enabling direct absorption through the oral mucosa, SL administration partially bypasses first-pass hepatic metabolism, potentially improving bioavailability and accelerating the onset of action for select med…
Neuropathic cancer pain (NCP) remains a formidable clinical adversary, severely compromising the quality of life for cancer survivors. Its pathogenesis is highly complex and multifactorial, bifurcated into tumor-induced and chemotherapy-induced neuropathic pain. This review dissects the intricate molecular mechanism of NCP, highlighting how the tumor microenvironment orchestrates neuro-tumor interaction. Bridging…
Background Opioids are the mainstay of cancer-related pain management but are limited by adverse effects and clinical complexity. Cannabinoids have been proposed as adjunctive, opioid-sparing agents, yet their impact on opioid consumption in cancer patients remains uncertain. Methods This systematic review and meta-analysis was conducted according to PRISMA 2020 guidelines and registered in PROSPERO (CRD4202511759…
BACKGROUND: Against the background of widely inconsistent data from randomized controlled trials (RCT), the use of cannabis-based medicines (CBM) from the perspective of patients with chronic non-cancer pain (CNCP) was described. METHODS: Based on a purposive/convenient sampling, patients were recruited from the Pain Clinic of Hannover Medical School who had been using CBM prescribed by a doctor for at least 6 mon…
BACKGROUND: Persistent, multimodal cancer pain remains a challenge, particularly in long-term survivors facing treatment-related complications. The management of high-dose opioid dependence concurrent with chronic, multi-drug resistant (MDR) periprosthetic infection presents a critical unmet need. This case reports the potential use and sustained efficacy of medical cannabis monotherapy, highlighting an unexpected…
Objective Strategies are needed for patients with chronic pain who are using opioids to safely and effectively wean opioids without worsening of pain. The objective was to measure associations between medical cannabis authorization (MCA) and opioid milligram equivalents (OME) in patients with chronic non-cancer pain. Design A longitudinal, retrospective cohort analysis from July 2016 to August 2019. Setting Electr…
Background Despite a growing volume of clinical research, cancer pain management remains dependent on opioid-centric paradigms with few therapeutic breakthroughs. To identify innovation gaps and guide future research, a systematic evaluation of the global clinical trial landscape is imperative. Methods We conducted a comprehensive landscape analysis of 632 interventional cancer pain trials(1994-2025) from the Tria…
Background Pancreatic ductal adenocarcinoma (PDAC) has a high incidence of perineural invasion (PNI), a pathological feature of the cancer invasion of nerves. PNI is associated with a poor prognosis, local recurrence and cancer pain. It has been suggested that interactions between nerves and the tumor microenvironment (TME) play a role in PDAC tumorigenesis. Methods Here, we used Nanostring GeoMx Digital Spatial P…
Background Opioid use and adverse events among cancer patients may change with access to medical marijuana. This study investigated the impacts of medical marijuana legalization (MML) since 2016. Methods Using a difference-in-differences approach and 2016 to 2022 private insurance claims data, this cross-sectional study included patients (aged 18-64 years) undergoing resection surgery for newly diagnosed (female)…
Background/Objectives: Chronic pain remains a pervasive and challenging public health issue, often resistant to conventional treatments such as opioids, which carry substantial risks of dependency and adverse effects. Cannabinoids, bioactive compounds derived from the Cannabis sativa plant and their synthetic analogs, have emerged as a potential alternative for pain management, leveraging their interaction with th…
Purpose of the review As cancer survival rates are increasing, alternative treatments to improve quality of life, such as cannabinoids, are gaining attention. Although cannabinoids are widely used to manage cancer-related symptoms, clear guidelines are lacking. This systematic review and meta-analysis assessed the safety and efficacy of cannabinoids in the management of symptoms among cancer patients. The study pr…
Chronic non-cancer pain, defined by the Center for Disease Control and Prevention (CDC) as lasting beyond three months, significantly affects individuals' quality of life and is often linked to various medical conditions or injuries. Its management is complex. Cannabis, containing the key compounds Delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), has garnered interest for its potential in pain management,…
Purpose Patients with cancer commonly access cannabis hoping to relieve their symptoms. This study assessed whether a 1:1 10 mg/ml THC:CBD combination oil could improve total symptom burden in patients with advanced cancer over that provided by palliative care alone. Methods Participants were randomised to medicinal cannabis (MC) or placebo oil; dose escalated over 14 days according to tolerance and efficacy and c…
BACKGROUND: Since its initial approval in 1992, medical cannabis (MC) in Israel has undergone extensive regulatory and structural transformation. This study aims to present the most comprehensive retrospective analysis to date of the evolving MC policy framework in Israel and its impact on patient access, prescribing patterns, and treatment characteristics from 2011 to 2025. METHODS: The study included a longitudi…
There is growing interest in using cannabinoids across various clinical scenarios, including pain medicine, leading to the disregard of regulatory protocols in some countries. Legislation has been implemented in Brazil, specifically in the state of São Paulo, permitting the distribution of cannabinoid products by health authorities for clinical purposes, free of charge for patients, upon professional prescription.…
Purpose To summarise the extent and type of evidence in relation to adverse events (AEs) associated with the use of cannabis-based products (CBP) in people living with cancer. Methods The Joanna Briggs Institute (JBI) methodology for scoping reviews was applied. A search was performed in MEDLINE (Ovid), Embase (Ovid), CINAHL (EBSCOhost), Scopus, Web of Science Core Collections and AMED (Ovid) from their inception…
Objective Marijuana use is increasingly common among patients with chronic non-cancer pain (CNCP) and long-term opioid therapy (LTOT). We determined if lifetime recreational and medical marijuana use were associated with more frequent and higher dose prescription opioid use. Design Cross-sectional SUBJECTS: Eligible patients (n=1,037), who had a new period of prescription opioid use lasting 30-90 days, were recrui…
In light of the current International Association for the Study of Pain (IASP) clinical practice guidelines (CPGs) and the European Society for Medical Oncology (ESMO) guidelines, the topic of cannabinoids in relation to pain remains controversial, with insufficient research presently available. Cannabinoids are an attractive pain management option due to their synergistic effects when administered with opioids, t…
Background Patients are surviving tumor diseases longer and longer due to the improvement of tumor-specific therapy and pain is a common symptom. The gold standard for tumor-associated chronic pain is multimodal therapy. Non-adherence causes high costs and may put patients at risk. The aim of this study was to investigate the adherence behavior and subjective treatment compliance of patients with tumor-associated…
To test the hypothesis that genetic and pharmacological modulation of the classical cannabinoid type 1 (CB1) and 2 (CB2) receptors attenuate cancer-induced bone pain, we searched Medline, Web of Science and Scopus for relevant skeletal and non-skeletal cancer studies from inception to July 28, 2022. We identified 29 animal and 35 human studies. In mice, a meta-analysis of pooled studies showed that treatment of os…